SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

SB-674042

Item No. 21270



CAS Registry No.:	483313-22-0
Formal Name:	[5-(2-fluorophenyl)-2-methyl-4-thiazolyl][(2S)-2-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]-1-pyrrolidinyl]-methanone
MF:	$C_{24}H_{21}FN_4O_2S$
FW:	448.5
Purity:	≥98%
UV/Vis.:	λ_{max}: 252 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SB-674042 is supplied as a crystalline solid. A stock solution may be made by dissolving the SB-674042 in the solvent of choice. SB-674042 is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of SB-674042 in these solvents is approximately 30 mg/ml.

Description

SB-674042 is a potent and selective non-peptide orexin 1 receptor (OX1R) antagonist (K_d = 5.03 and 3.76 nM in whole cell binding and membrane-based assays, respectively).[1] In calcium mobilization studies, it was >100-fold selective for OX1 over OX2 and did not show significant affinity for serotonergic, dopaminergic, adrenergic, or purinergic receptors at concentrations up to 10 µM.[2]

References

1. Langmead, C. J., Jerman, J.C., Brough, S.J., *et al.* Characterisation of the binding of 3H-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. *Br. J. Pharmacol.* **141(2)**, 340-346 (2004).
2. Ellis, J., Pediani, J.D., Canals, M., *et al.* Orexin-1 receptor-cannabinoid CB_1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. *J. Biol. Chem.* **281(50)**, 38812-38824 (2006).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM